Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
Merck negotiates potential acquisition of Revolution Medicines for up to $32B, seeking new cancer treatments as Keytruda patent expiration looms in 2028.
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Adagene receives FDA Fast Track designation for muzastotug, a novel cancer therapy targeting hard-to-treat colorectal cancer patients.
Anixa Biosciences announced positive Phase 1 data for its investigational breast cancer vaccine, showing strong safety and immune response results in 74% of participants.
